Recent Updates
Recently added Catalysts

Combination IOP Lowering Therapy

Phase 2

Glaucoma, Open-angle | Small molecule | Cardiovascular |Alcon Inc.|Last Updated: Apr 16, 2012

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
RandomizedDouble-BlindUNCONTROLLED
Total Trials1
Total Enrollment -
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT00051194A 6-week Safety & Efficacy Study of Combination Intraocular Pressure-lowering Therapy in Patients With Open-angle Glaucoma or Ocular HypertensionPHASE2 COMPLETED -Sep 1, 2002Jul 1, 2003Apr 16, 20121 United States
Unlock Drug Trial Details
Study Design & Arms
AllocationRANDOMIZED
MaskingDOUBLE
ModelPARALLEL
PurposeTREATMENT
Interventions
NameTypeDescription
Combination IOP Lowering TherapyDRUG -
Unlock Study Design Details
Eligibility Criteria
Age Range18 Years — N/A
SexALL
Healthy VolunteersNo
Study Sites1

Adult patients of any race and either sex with open angle glaucoma or ocular hypertension.

Countries:United States
Unlock Eligibility Criteria